Literature DB >> 9617787

Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease.

F C Cheng1, J S Kuo, L G Chia, G Dryhurst.   

Abstract

High-performance liquid chromatography with electrochemical detection has been employed to analyze ultrafiltrates of cerebrospinal fluid of Parkinson's Disease (PD) patients and age-matched controls for the dopamine (DA) metabolites homovanillic acid (HVA) and 5-S-cysteinyldopamine (5-S-CyS-DA). The mean level of HVA in the CSF of PD patients, measured 5 days after withdrawal from L-DOPA therapy, was significantly lower than that measured in controls. By contrast, mean levels of 5-S-CyS-DA were not significantly different in the CSF of PD patients taking L-DOPA (PD-LT patients) the same patients 5 days after discontinuing this drug (PD-LW patients) or controls. However, the mean 5-S-CyS-DA/HVA concentration ratio was significantly (p < 0.05) higher in the CSF of PD-LW patients compared to controls. Although the PD patient population employed in this study had been diagnosed with the disease several years previously and had been treated with L-DOPA for prolonged periods of time the results of this study suggest that low CSF levels of HVA and a high 5-S-CyS-DA/HVA ratio together might represent useful markers for early diagnosis of PD. The high 5-S-CyS-DA/HVA ratio observed in the CSF of PD-LW patients also provides support for the hypothesis that the translocation of glutathione or L-cysteine into neuromelanin-pigmented dopaminergic cell bodies in the substantia nigra might represent an early event in the pathogenesis of PD.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9617787     DOI: 10.1007/BF01276419

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  44 in total

1.  Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones.

Authors:  D G Graham
Journal:  Mol Pharmacol       Date:  1978-07       Impact factor: 4.436

2.  Regional distribution of malonaldehyde in mouse brain.

Authors:  V Calabrese; R G Fariello
Journal:  Biochem Pharmacol       Date:  1988-06-01       Impact factor: 5.858

3.  Biochemical pathophysiology of Parkinson's disease.

Authors:  O Hornykiewicz; S J Kish
Journal:  Adv Neurol       Date:  1987

4.  Imbalance of brain monoamines and clinical disorders.

Authors:  O Hornykiewicz
Journal:  Prog Brain Res       Date:  1982       Impact factor: 2.453

5.  Catechol metabolites in the cerebrospinal fluid as possible markers in the early diagnosis of Parkinson's disease.

Authors:  A Carlsson; B Fornstedt
Journal:  Neurology       Date:  1991-05       Impact factor: 9.910

6.  Detection of 5-S-cysteinyldopamine in human brain.

Authors:  E Rosengren; E Linder-Eliasson; A Carlsson
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

Review 7.  Post-mortem distribution of dopamine and homovanillic acid in human brain, variations related to age, and a review of the literature.

Authors:  R Adolfsson; C G Gottfries; B E Roos; B Winblad
Journal:  J Neural Transm       Date:  1979       Impact factor: 3.575

8.  The neuromelanin of the human substantia nigra.

Authors:  R Carstam; C Brinck; A Hindemith-Augustsson; H Rorsman; E Rosengren
Journal:  Biochim Biophys Acta       Date:  1991-09-23

9.  Regional distribution of ubiquinones and tocopherols in the mouse brain: lowest content of ubiquinols in the substantia nigra.

Authors:  R G Fariello; O Ghilardi; A Peschechera; M T Ramacci; L Angelucci
Journal:  Neuropharmacology       Date:  1988-10       Impact factor: 5.250

10.  Dopamine deficiency in the cerebral cortex in Parkinson disease.

Authors:  B Scatton; L Rouquier; F Javoy-Agid; Y Agid
Journal:  Neurology       Date:  1982-09       Impact factor: 9.910

View more
  20 in total

1.  Liposomal-glutathione provides maintenance of intracellular glutathione and neuroprotection in mesencephalic neuronal cells.

Authors:  Gail D Zeevalk; Laura P Bernard; F T Guilford
Journal:  Neurochem Res       Date:  2010-06-10       Impact factor: 3.996

Review 2.  Cognitive impairment and dementia in patients with Parkinson disease.

Authors:  James B Leverenz; Joseph F Quinn; Cyrus Zabetian; Jing Zhang; Kathleen S Montine; Thomas J Montine
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

3.  Glutathione transferase-M2-2 secreted from glioblastoma cell protects SH-SY5Y cells from aminochrome neurotoxicity.

Authors:  Carlos Cuevas; Sandro Huenchuguala; Patricia Muñoz; Monica Villa; Irmgard Paris; Bengt Mannervik; Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2014-11-18       Impact factor: 3.911

4.  Elevated cerebrospinal fluid ratios of cysteinyl-dopamine/3,4-dihydroxyphenylacetic acid in parkinsonian synucleinopathies.

Authors:  David S Goldstein; Courtney Holmes; Patricia Sullivan; Yunden Jinsmaa; Irwin J Kopin; Yehonatan Sharabi
Journal:  Parkinsonism Relat Disord       Date:  2016-07-20       Impact factor: 4.891

Review 5.  The aetiology of idiopathic Parkinson's disease.

Authors:  D B Ramsden; R B Parsons; S L Ho; R H Waring
Journal:  Mol Pathol       Date:  2001-12

6.  Biopterin levels in the cerebrospinal fluid of patients with PARK8 (I2020T).

Authors:  Shoko Koshiba; Hirofumi Tokuoka; Teruo Yokoyama; Emiko Horiuchi; Hiroshi Ichinose; Kazuko Hasegawa
Journal:  J Neural Transm (Vienna)       Date:  2011-02-03       Impact factor: 3.575

7.  Glutathione transferase mu 2 protects glioblastoma cells against aminochrome toxicity by preventing autophagy and lysosome dysfunction.

Authors:  Sandro Huenchuguala; Patricia Muñoz; Patricio Zavala; Mónica Villa; Carlos Cuevas; Ulises Ahumada; Rebecca Graumann; Beston F Nore; Eduardo Couve; Bengt Mannervik; Irmgard Paris; Juan Segura-Aguilar
Journal:  Autophagy       Date:  2014-01-14       Impact factor: 16.016

8.  Model neuromelanins as antioxidative agents during lipid peroxidation.

Authors:  T Wilczok; K Stepien; A Dzierzega-Lecznar; A Zajdel; A Wilczok
Journal:  Neurotox Res       Date:  1999-12       Impact factor: 3.911

9.  The neurotoxicity of glutamate, dopamine, iron and reactive oxygen species: functional interrelationships in health and disease: a review-discussion.

Authors:  J Smythies
Journal:  Neurotox Res       Date:  1999-09       Impact factor: 3.911

Review 10.  Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease.

Authors:  Masato Asanuma; Ikuko Miyazaki; Norio Ogawa
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.